Mylan (NASDAQ:MYL) Director Robert J. Coury sold 50,000 shares of the company’s stock in a transaction on Tuesday, March 6th. The stock was sold at an average price of $43.41, for a total transaction of $2,170,500.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.
Robert J. Coury also recently made the following trade(s):
- On Friday, March 2nd, Robert J. Coury sold 150,000 shares of Mylan stock. The stock was sold at an average price of $40.10, for a total transaction of $6,015,000.00.
Mylan (NASDAQ:MYL) traded down $0.43 during midday trading on Tuesday, reaching $42.35. 3,460,000 shares of the company’s stock traded hands, compared to its average volume of 5,580,000. The stock has a market capitalization of $22,020.00, a P/E ratio of 32.58, a PEG ratio of 1.35 and a beta of 1.35. Mylan has a 1-year low of $29.39 and a 1-year high of $47.82. The company has a debt-to-equity ratio of 1.06, a quick ratio of 0.73 and a current ratio of 1.13.
Mylan (NASDAQ:MYL) last released its quarterly earnings data on Wednesday, February 28th. The company reported $1.43 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.41 by $0.02. The business had revenue of $3.24 billion for the quarter, compared to the consensus estimate of $3.29 billion. Mylan had a net margin of 5.84% and a return on equity of 19.14%. The company’s revenue was down .9% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.57 earnings per share. equities research analysts expect that Mylan will post 5.38 EPS for the current fiscal year.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in MYL. BT Investment Management Ltd purchased a new stake in Mylan during the third quarter valued at about $142,000. Rational Advisors LLC purchased a new stake in Mylan during the fourth quarter valued at about $190,000. First Personal Financial Services lifted its holdings in Mylan by 77.1% during the fourth quarter. First Personal Financial Services now owns 4,839 shares of the company’s stock valued at $205,000 after purchasing an additional 2,106 shares during the last quarter. Lombard Odier Asset Management Europe Ltd purchased a new stake in Mylan during the fourth quarter valued at about $209,000. Finally, Mycio Wealth Partners LLC purchased a new stake in Mylan during the fourth quarter valued at about $212,000. 84.82% of the stock is currently owned by institutional investors and hedge funds.
Several analysts have recently issued reports on MYL shares. TheStreet upgraded shares of Mylan from a “c” rating to a “b-” rating in a research note on Wednesday, January 17th. Citigroup reiterated a “buy” rating and issued a $58.00 target price (up previously from $48.00) on shares of Mylan in a research note on Thursday, January 4th. Guggenheim assumed coverage on shares of Mylan in a research note on Tuesday, December 12th. They issued a “buy” rating and a $59.00 target price for the company. UBS Group set a $46.00 price target on shares of Mylan and gave the company a “buy” rating in a research report on Monday, December 4th. Finally, ValuEngine upgraded shares of Mylan from a “hold” rating to a “buy” rating in a research report on Friday, December 1st. Nine equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. Mylan presently has a consensus rating of “Buy” and an average price target of $45.92.
ILLEGAL ACTIVITY NOTICE: This news story was originally posted by Week Herald and is the property of of Week Herald. If you are viewing this news story on another publication, it was stolen and republished in violation of United States and international copyright laws. The correct version of this news story can be viewed at https://weekherald.com/2018/03/13/mylan-myl-director-robert-j-coury-sells-50000-shares.html.
Mylan Company Profile
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
Receive News & Ratings for Mylan Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Mylan and related companies with MarketBeat.com’s FREE daily email newsletter.